These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23529741)

  • 1. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
    Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
    Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
    Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients.
    Karthaus M; Doellmann T; Klimasch T; Elser C; Rosenthal C; Ganser A; Heil G
    Chemotherapy; 2000; 46(4):293-302. PubMed ID: 10859435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
    Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
    Chong GL; Broekman F; Polinder S; Doorduijn JK; Lugtenburg PJ; Verbon A; Cornelissen JJ; Rijnders BJ
    Int J Antimicrob Agents; 2015 Jul; 46(1):82-7. PubMed ID: 25956843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
    Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
    Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
    Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.
    Giannella M; Ercolani G; Cristini F; Morelli M; Bartoletti M; Bertuzzo V; Tedeschi S; Faenza S; Puggioli C; Lewis RE; Pinna AD; Viale P
    Transplantation; 2015 Apr; 99(4):848-54. PubMed ID: 25531982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.
    Gubbins PO; Amsden JR; McConnell SA; Anaissie EJ
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3664-74. PubMed ID: 19546359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.
    Sunakawa K; Tsukimoto I; Tsunematsu Y; Honda M; Iwai N; Maniwa T; Haigo H; Suzuki K; Mori T
    J Infect Chemother; 2012 Aug; 18(4):456-65. PubMed ID: 22286407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.
    Seibel NL; Shad AT; Bekersky I; Groll AH; Gonzalez C; Wood LV; Jarosinski P; Buell D; Hope WW; Walsh TJ
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Döring M; Hartmann U; Erbacher A; Lang P; Handgretinger R; Müller I
    BMC Infect Dis; 2012 Jul; 12():151. PubMed ID: 22747637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.
    Cornely OA; Leguay T; Maertens J; Vehreschild MJGT; Anagnostopoulos A; Castagnola C; Verga L; Rieger C; Kondakci M; Härter G; Duarte RF; Allione B; Cordonnier C; Heussel CP; Morrissey CO; Agrawal SG; Donnelly JP; Bresnik M; Hawkins MJ; Garner W; Gökbuget N;
    J Antimicrob Chemother; 2017 Aug; 72(8):2359-2367. PubMed ID: 28575414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
    Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
    Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.
    Javandoust Gharehbagh F; Roshanzamiri S; Farjami M; Hatami F; Lotfollahi L; Kazeminia N; Hatami F; Shokouhi S; Alavi Darazam I
    J Oncol Pharm Pract; 2024 Jul; 30(5):919-929. PubMed ID: 38720564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy and safety of liposomal amphotericin B in the salvage treatment of invasive fungal disease in patients with hematological diseases].
    Wu YB; Jiang SS; Wu YX; Liu B; Jing YT; Bao HY; Ma X; Wu DP; Hu XH
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jul; 45(7):666-671. PubMed ID: 39231771
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the safety and cost-effectiveness of nebulized liposomal amphotericin B and amphotericin B deoxycholate for antifungal prophylaxis after lung transplantation.
    Umemura K; Katada Y; Nakagawa S; Hira D; Yutaka Y; Tanaka S; Ohsumi A; Nakajima D; Date H; Nagao M; Terada T
    J Infect Chemother; 2024 Aug; 30(8):741-745. PubMed ID: 38354908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.